P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas.
about
The molecular pathology of ovarian serous borderline tumors.Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.Clinicopathologic significance of claudin-6, occludin, and matrix metalloproteinases -2 expression in ovarian carcinoma.
P2860
P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
P53, MAPK, topoisomerase II al ...... in ovarian serous carcinomas.
@ast
P53, MAPK, topoisomerase II al ...... in ovarian serous carcinomas.
@en
type
label
P53, MAPK, topoisomerase II al ...... in ovarian serous carcinomas.
@ast
P53, MAPK, topoisomerase II al ...... in ovarian serous carcinomas.
@en
prefLabel
P53, MAPK, topoisomerase II al ...... in ovarian serous carcinomas.
@ast
P53, MAPK, topoisomerase II al ...... in ovarian serous carcinomas.
@en
P2093
P2860
P356
P1433
P1476
P53, MAPK, topoisomerase II al ...... in ovarian serous carcinomas.
@en
P2093
Branka Petric Mise
Dijana Gugic
Dinka Sundov
Irena Drmic Hofman
Ivana Mrklic
Snjezana Tomic
Vesna Capkun
P2860
P2888
P356
10.1186/1746-1596-8-21
P577
2013-02-06T00:00:00Z
P5875
P6179
1011659067